{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:40:26Z","timestamp":1715960426877},"reference-count":27,"publisher":"Computers, Materials and Continua (Tech Science Press)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2012,8,13]]},"abstract":"<jats:p>Leiomyosarcoma represents about 24% of all soft tissue sarcomas and can originate from retroperitoneum, uterus, or extremities. Adequate local control may be achieved with surgery and radiotherapy. In the presence of unresectable metastases either doxorubicin- or gemcitabine-based chemotherapy\n is the standard of treatment. Nevertheless, prognosis remains poor regardless of the selected chemotherapy regimen, and new effective therapeutic agents for patients with advanced leiomyosarcoma are needed. Trabectedin, a promising new DNA-damaging agent with a mechanism of action that is\n different from that of traditional alkylating agents, is approved in Europe for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents and in combination with pegylated liposomal doxorubicin (PLD)\n for the treatment of patients with relapsed platinum-sensitive ovarian cancer. We present a case of a 76-year-old patient with progressive metastatic lung lesions from a previously resected primary leiomyosarcoma of the thigh and moderate renal failure, who achieved 17 months of disease stability\n during third-line treatment with trabectedin. Trabectedin was not associated with any cumulative toxicity and was consistently well tolerated for a total of 22 treatment cycles. Current evidence on trabectedin is also presented.<\/jats:p>","DOI":"10.3727\/096504013x13685487925130","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T01:17:04Z","timestamp":1375924624000},"page":"483-490","source":"Crossref","is-referenced-by-count":5,"title":["Prolonged Disease Stability With Trabectedin in a Heavily Pretreated Elderly Patient With Metastatic Leiomyosarcoma of the Thigh and Renal Failure: A Case Report and Review of the Literature"],"prefix":"10.32604","volume":"20","author":[{"given":"Danilo","family":"Galizia","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Institute for Cancer Research and Treatment, Fondazione del Piemonte per l\u2019 Oncologia Candiolo, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Palesandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ymera","family":"Pignochino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Aglietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Grignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","reference":[{"key":"b1","first-page":"1409","article-title":"Sarcoma","volume":"8","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"b2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-0560.2009.01405.x","article-title":"Superficial leiomyosarcoma: A clinicopathologic review and update","volume":"37","year":"2010","journal-title":"J. Cutan. Pathol."},{"key":"b3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/cncr.22395","article-title":"Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group","volume":"109","year":"2007","journal-title":"Cancer"},{"key":"b4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11912-011-0173-0","article-title":"Novel approaches to treatment of leiomyosarcomas","volume":"13","year":"2011","journal-title":"Curr. Oncol. Rep."},{"key":"b5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11864-011-0140-x","article-title":"Histology-driven chemotherapy in soft tissue sarcomas","volume":"12","year":"2011","journal-title":"Curr. Treat. Options Oncol."},{"key":"b6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","article-title":"Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens\u2014a European Organization for Research and Treatment of Cancer Soft Tissue and Bone","volume":"17","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"b7","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of Sarcoma Alliance for Research through Collaboration Study 002","volume":"25","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"b8","first-page":"1879","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","year":"2012","journal-title":"Lancet"},{"key":"b9","first-page":"355","article-title":"Trabectedin: A review of its use in soft tissue sarcoma and ovarian cancer","volume":"70","year":"2010","journal-title":"Drugs"},{"key":"b10","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): A unique mechanism of action","volume":"9","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"b11","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00280-011-1718-5","article-title":"Pharmacokinetics of trabectedin on hemodialysis: An application for the management of cancer patients with end-stage renal disease","volume":"68","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"b12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"b13","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/0008-5472.CAN-09-2335","article-title":"Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells","volume":"70","year":"2010","journal-title":"Cancer Res."},{"key":"b14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ejca.2011.01.016","article-title":"Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study","volume":"47","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"b15","doi-asserted-by":"crossref","first-page":"8231","DOI":"10.1158\/0008-5472.CAN-09-2543","article-title":"A role for BRCA1 in uterine leiomyosarcoma","volume":"69","year":"2009","journal-title":"Cancer Res."},{"key":"b16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ygyno.2011.08.016","article-title":"Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers","volume":"123","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"b17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2011.09.019","article-title":"A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study","volume":"124","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"b18","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules","volume":"27","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"b19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S1359-6349(09)72015-4","article-title":"Efficacy of second-line trabectedin in patients with advanced liposarcomas and leiomyosarcomas progressing despit prior conventional chemotherapy [abstract 9427]","volume":"7","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"b20","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1359-6349(09)71989-5","article-title":"Translocation-related sarcomas (TRS): A retrospective analysis of activity with trabectedin [abstract 9401]","volume":"7","year":"2009","journal-title":"Eur J. Cancer"},{"key":"b21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1359-6349(09)71990-1","article-title":"Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are indpendent of patient age [abstract 9402]","volume":"7","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"b22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.seminoncol.2009.06.004","article-title":"Translocation-related sarcomas","volume":"36","year":"2009","journal-title":"Semin. Oncol."},{"key":"b23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study","volume":"8","year":"2007","journal-title":"Lancet Oncol."},{"key":"b24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00280-012-1864-4","article-title":"A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin","volume":"69","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"b25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CCO.0b013e32833aaac1","article-title":"Trabectedin therapy for sarcomas","volume":"22","year":"2010","journal-title":"Curr. Opin. Oncol."},{"key":"b26","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ejca.2006.02.010","article-title":"Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma","volume":"42","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"b27","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00280-011-1614-z","article-title":"Trabectedin has a low cardiac risk profile: A comprehensive cardiac safety analysis","volume":"68","year":"2011","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/cog\/or\/2012\/00000020\/00000010\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T10:06:00Z","timestamp":1658138760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.3727\/096504013X13685487925130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,13]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,8,13]]}},"alternative-id":["0965-0407(20120813)20:10L.483;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504013x13685487925130","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,13]]}}}